Bionanotechnology II: Drug Delivery - Ola Nerbrink
Recent Trends in Nanodrug Delivery - Innovative Technologies and Commercial ViabilityOne of the greatest impacts of nanomedicine is likely to take place in the context of drug delivery, which is poised to deliver to the market both evolutionary and revolutionary nanomedicines and devices.
Early forecasts for nanomedicine commercialization are encouraging.
However, there are challenges as well […]
The Future of Device Biologics
This timely presentation by AnneMarie Moseley, CEO, Aggregate Therapeutics, explores the impact of the converging medical device and biologic industries on the development of regenerative medicine products.
By assessing the influence of combination product regulations on both biologic and device products, it provides a necessary focus on the timeliness and cost of device-biologic development and […]
The Evolution of the Pharmaceutical Industry Blogosphere
One of the first bloggers to focus on drug industry marketing, ethics and policy was John Mack, journalist and publisher of the popular e-newsletter Pharma Marketing News. Mack’s candid and timely commentary earned him a mention in the Wall Street Journal as a must-read blog for industry insiders.
Over the past two […]
The Life Science Start-up…Funding—How Much is Enough?
Please read the following case study in advance of watching the above video, which is the case being discussed by a panel of life sciences and venture capital experts at the BioStrategy Partners Conference - First Sightings 2007: Resources for Emerging Life Science Companies.
Joseph Smith is a talented scientist with a Ph.D. in biomedical engineering, […]
HealthDot Pharma Report - April 13, 2007
In Episode II of the HealthDot Pharma Report we start at the intersection of Social Security, children’s health, pharmaceuticals and alleged murder.
Prosecutors in Brockton, Massachusetts charged two parents with killing their daughter by overdosing her on prescription drugs.
The case alleges that Michael and Carolyn Riley sought Supplemental Security Income, a program administered by the Social […]
Rethinking The Business of Pharma
About the Video
This video was shot at ScribeMedia in advance of Re:Think 2007 — The 53rd Annual ARF Convention.
About re:Think
Re:Think 2007 will bring all the leading-edge players together – top-tier advertisers, agencies, media, research and interactive shops on April 16 — 18.
Registration Information
Visit the ARF to register and for more information.
Three advertising experts sit down […]
Pharmalot Pharmalittle
I had a chance to sit down with Ed Silverman of Pharmalot. Pharmalot is a pharmaceutical focused blog owned by the Star Ledger of New Jersey, which in turn is owned by NewHouse.
While the Star Ledger is for Jersey Joe, Pharmalot is for Pharma Phil, regardless of his geography. It is designed to be a […]
HealthDot Pharma Report - March 10, 2007
Video: In this episode of the HealthDot Pharma Report we talk business with Ogilvy Healthworld’s Frank Hone, explore Genentech’s Macular Degeneration conundrum with Dr. William Rich, Medical Director of Health Policy at the American Academy of Opthalmology, discuss drug re-importation and follow congressional debates surrounding biologics.
Social Media and Pharma Marketing
I had a chance to sit down with Frank Hone, Executive Vice President, Ogilvy Healthworld, to talk about the changing landscape of consumer advertising in the Pharmaceutical industry. We talked about social media, engaging consumers through search, health related web sites, and even product / brand web sites.
Frank talks about the evolution towards better and […]
Genentech’s Two Headed Monster: Lucentis and Avastin
Genentech, the Biotech powerhouse, has a problem. They’re too good at what they do. The company has two drugs that both do a fantastic job treating the same disease - age-related macular degeneration (
